The National Institute for Health and Care Excellence

The device that raised the alarm and saved my life

Gavin Redhead, a patient advocate, tells us how heart failure healthtech recommended by NICE helped transform his life.
The National Institute for Health and Care Excellence

Thousands eligible for new chronic heart failure treatment following NICE recommendation

Thousands of people in England with a type of chronic heart failure are eligible for a new treatment option following our final draft guidance that recommends finerenone for adults with chronic heart ...
National Institute for Health and Care Excellence

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

Evidence-based recommendations on amivantamab (Rybrevant) with carboplatin and pemetrexed for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.
National Institute for Health and Care Excellence

Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over

This guidance updates and replaces NICE technology appraisal guidance on ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088). Next review: This guidance will be ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency

Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair ...
National Institute for Health and Care Excellence

Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

There is a simple discount patient access scheme for talquetamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable

There is a simple discount patient access scheme for isatuximab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact GB-PatientAccess ...
National Institute for Health and Care Excellence

Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com ...
National Institute for Health and Care Excellence

Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence

There is a simple discount patient access scheme for ribociclib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

There is a simple discount patient access scheme for nivolumab, and a patient access scheme plus commercial access agreement for ipilimumab. NHS organisations can get details on the Commercial Access ...